Trial Profile
An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Alexion Pharmaceuticals
- 07 Nov 2015 New source identified and integrated (ClinicalTrials.gov NCT00867932).